This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Need Defense? Think Medical Supplies

Conventional wisdom says investing in health care is a smart way to defend against tough economic times.

These days, however, purchasers of many defensive stocks, from major pharmaceuticals to large biotechs to big-name device makers, are suffering from offensive returns.

Still, there's an island of cheer amid this medical malaise. When it comes to a good defense, you can't beat catheters, syringes, needles, instruments and hospital supplies. In other words, you can't beat companies like C.R. Bard (BCR - Get Report) and Becton Dickinson (BDX - Get Report).

Many analysts forecast a continuing, comparatively strong showing for these firms and some of their peers. "Historically, falling [interest] rates and decelerating corporate profits bode well for defensive med-tech stocks, as does a weaker dollar," says a recent analysis by JPMorgan.

There's a tortoise-and-hare quality to Bard and Becton Dickinson vs. major drugmakers such as Merck (MRK - Get Report) or large biotechs like Amgen (AMGN - Get Report).

The latter companies have enjoyed jackrabbit stock gains when they produce blockbusters, but all have slumped when something went wrong in clinical testing, in the marketplace or with regulators.

With Bard and Becton Dickinson, slow and steady wins the race. Because they make many products, they can better absorb disappointments, setbacks and even recalls.

For the 12 months ended April 2, Bard was up 22%, and Becton Dickinson gained 15%. The S&P 500 was down 8%, while the Amex indices for both large drugmakers and major biotechs lost 12%.

During this period, Bard and Becton Dickinson easily outscored device-makers such as Medtronic (MDT - Get Report) and Boston Scientific (BSX - Get Report). Although they also sell many products, the device makers have soared and sagged with their respective signature devices -- implantable cardioverter defibrillators and drug-coated cardiac stents.

For the five years ended April 2, the slow-but-steady crowd produced even better stock results. Becton Dickinson gained 170%. On a split-adjusted basis, Bard was up about 200%, or four times the growth rate of the S&P 500 and nearly double the gain of the Amex Biotech Index. The Amex big-drug index barely broke even. Medtronic was narrowly in the black, while Boston Scientific was in the red.

Tough Competition

Bard, Becton Dickinson and their peers battle on many treatment fronts, including urology, diabetes, hernia repair, circulatory system problems and cancer care, as well as drug-delivery products and general surgical supplies. Competitors can be small companies focusing on few treatment areas, or health care conglomerates such as Johnson & Johnson (JNJ - Get Report) and Baxter International (BAX).

Because of the commodity-like nature of many products and the maturing of U.S. markets in certain treatment areas, Bard and Becton Dickinson have succeeded by improving old products, finding new markets and diversifying.

"In the rapidly evolving medical-device field, continuing innovation is the key to prolonged success, as differentiation advantages erode quickly and rivalries intensify," says Alex Morozov of the independent research firm Morningstar, in a recent report.

Diversification has obvious benefits, but it also holds risks, because efforts to develop more complex, higher-margin products could backfire, analysts say. Becton Dickinson, for example, entered the blood-glucose monitor field in 2003 and quit three years later.

Wall Street also wonders whether the hospital-supply companies can sustain or improve their growth rates or whether their current share prices have outpaced their fundamentals. Bard, which has a market capitalization of $9.9 billion, has a buy-hold ratings ratio of 3-to-7, according a Thomson First Call poll of analysts. Becton Dickinson, whose market cap is $21 billion, has a buy-hold ratio of 6-to-5.

Becton Dickinson's path to continued growth depends partly on its ability to sell traditional surgical products in "rapidly growing European and Asian markets," says Morozov, in a research report. But the biggest source of growth will be its roster of products used in pharmaceutical and biotech R&D and its diagnostics business. In recent years, Becton Dickinson acquired two small companies to improve the diagnosis of cancer and drug-resistant bacterial infections.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $141.16 -2.70%
BCR $179.75 -1.70%
BDX $131.18 -3.00%
BSX $16.05 -3.40%
JNJ $102.31 1.80%


Chart of I:DJI
DOW 15,882.55 -322.42 -1.99%
S&P 500 1,836.68 -43.37 -2.31%
NASDAQ 4,242.0150 -121.1290 -2.78%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs